BioSpace News Archive

Business

Genetown Companies Invest in Future Talent With Academic Programs

Boston and its surrounding communities, particularly the community of Cambridge, have become the hottest biotech hotspot on the East Coast of the United States.

May 8, 2019
·
3 min read
·
Alex Keown
Pharm Country

Regeneron Discloses Two Deaths from its Bispecific Antibody RGN1979

Shares of Regeneron fell more than 6 percent Tuesday after the company disclosed two deaths related to its vaunted bispecific antibody program.

May 8, 2019
·
2 min read
·
Alex Keown
Drug Development

AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Hits Primary Endpoint

The primary endpoint was objective response rate (ORR). Secondary objectives included duration of response, disease control rate, clinical benefit rate, progression-free survival and overall survival.

May 8, 2019
·
3 min read
·
Mark Terry
Business

Gilead and Goldfinch Bio Enter $2 Billion-Plus Partnership to Develop Kidney Disease Drugs

Under the terms of the deal, Gilead holds exclusive options to license worldwide rights to specific products directed toward targets coming out of Goldfinch’s proprietary Kidney Genome Atlas.

May 8, 2019
·
2 min read
·
Mark Terry
Policy

BioSpace’s Global Biopharma Roundup: May 9

Companies from across the globe provide updates to their pipelines and businesses, with news from BioNTech, Mologic, Akcea, RedHill, and more.

May 8, 2019
·
4 min read
·
Alex Keown
Business

Allergan CEO: Company Looking at All Options to Boost Share Price

With key investors upset about Allergan’s share price, Saunders pointed to five potential drugs on the market within the next 18 months.

May 8, 2019
·
3 min read
·
Alex Keown
Business

Sarepta Adds a Sixth LGMD Gene Therapy Candidate to its Arsenal

Sarepta struck a deal with the Research Institute at Nationwide Children’s Hospital for the gene therapy candidate, calpain 3.

May 8, 2019
·
2 min read
·
Alex Keown
Deals

Pfizer Acquires Rare-Drug Company Therachon for $810 Million

Under the terms of the deal, Pfizer will pay $340 million up front with another $470 million in payments contingent on milestones for the development and commercialization of TA-46 for the treatment of achondroplasia.

May 8, 2019
·
3 min read
·
Mark Terry
Job Trends

RefleXion Adds Manufacturing Space, 50 Employees as it Prepares for Launch of Radiotherapy System

RefleXion will open a 50,000-square-foot manufacturing site later this month and add 50 employees by the end of the year.

May 8, 2019
·
2 min read
·
Alex Keown
Business

Mispro Announces Opening of Vivarium Research Facility in Farmingdale, NY

Vivarium Space & Services Provider Expands its Network to Long Island Bioscience Park

May 8, 2019
·
4 min read